Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

A visible-light mediated three-component radical process using dithiocarbamate anion catalysis.

Cuadros S, Horwitz MA, Schweitzer-Chaput B, Melchiorre P.

Chem Sci. 2019 Apr 30;10(21):5484-5488. doi: 10.1039/c9sc00833k. eCollection 2019 Jun 7.

2.

Nanomachines and Other Caps on Mesoporous Silica Nanoparticles for Drug Delivery.

Chen W, Glackin CA, Horwitz MA, Zink JI.

Acc Chem Res. 2019 Jun 18;52(6):1531-1542. doi: 10.1021/acs.accounts.9b00116. Epub 2019 May 13.

PMID:
31082188
3.

Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.

Clemens DL, Lee BY, Silva A, Dillon BJ, Masleša-Galić S, Nava S, Ding X, Ho CM, Horwitz MA.

PLoS One. 2019 May 10;14(5):e0215607. doi: 10.1371/journal.pone.0215607. eCollection 2019. Erratum in: PLoS One. 2019 May 30;14(5):e0217670.

4.

Photochemical generation of radicals from alkyl electrophiles using a nucleophilic organic catalyst.

Schweitzer-Chaput B, Horwitz MA, de Pedro Beato E, Melchiorre P.

Nat Chem. 2019 Feb;11(2):129-135. doi: 10.1038/s41557-018-0173-x. Epub 2018 Dec 3.

PMID:
30510217
5.

Nanoparticle Formulation of Moxifloxacin and Intramuscular Route of Delivery Improve Antibiotic Pharmacokinetics and Treatment of Pneumonic Tularemia in a Mouse Model.

Clemens DL, Lee BY, Plamthottam S, Tullius MV, Wang R, Yu CJ, Li Z, Dillon BJ, Zink JI, Horwitz MA.

ACS Infect Dis. 2019 Feb 8;5(2):281-291. doi: 10.1021/acsinfecdis.8b00268. Epub 2018 Dec 10.

PMID:
30480992
6.

PPE37 Is Essential for Mycobacterium tuberculosis Heme-Iron Acquisition (HIA), and a Defective PPE37 in Mycobacterium bovis BCG Prevents HIA.

Tullius MV, Nava S, Horwitz MA.

Infect Immun. 2019 Jan 24;87(2). pii: e00540-18. doi: 10.1128/IAI.00540-18. Print 2019 Feb.

7.

Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility.

Lee BY, Clemens DL, Silva A, Dillon BJ, Masleša-Galić S, Nava S, Ho CM, Horwitz MA.

PLoS One. 2018 Nov 14;13(11):e0207469. doi: 10.1371/journal.pone.0207469. eCollection 2018.

8.

Facile Strategy Enabling Both High Loading and High Release Amounts of the Water-Insoluble Drug Clofazimine Using Mesoporous Silica Nanoparticles.

Chen W, Cheng CA, Lee BY, Clemens DL, Huang WY, Horwitz MA, Zink JI.

ACS Appl Mater Interfaces. 2018 Sep 26;10(38):31870-31881. doi: 10.1021/acsami.8b09069. Epub 2018 Sep 13.

PMID:
30160469
9.

Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With Virulent F. tularensis subsp. tularensis.

Jia Q, Horwitz MA.

Front Cell Infect Microbiol. 2018 May 15;8:154. doi: 10.3389/fcimb.2018.00154. eCollection 2018. Review.

10.

The Francisella Type VI Secretion System.

Clemens DL, Lee BY, Horwitz MA.

Front Cell Infect Microbiol. 2018 Apr 23;8:121. doi: 10.3389/fcimb.2018.00121. eCollection 2018. Review.

11.

Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.

Jia Q, Bowen R, Dillon BJ, Masleša-Galić S, Chang BT, Kaidi AC, Horwitz MA.

Sci Rep. 2018 May 3;8(1):7009. doi: 10.1038/s41598-018-24581-y.

12.

Asymmetric Organocatalytic Sulfa-Michael Addition to Enone Diesters.

Fulton JL, Horwitz MA, Bruske EL, Johnson JS.

J Org Chem. 2018 Mar 16;83(6):3385-3391. doi: 10.1021/acs.joc.8b00007. Epub 2018 Mar 7.

13.

Enantio- and Diastereoselective Organocatalytic Conjugate Additions of Nitroalkanes to Enone Diesters.

Horwitz MA, Fulton JL, Johnson JS.

Org Lett. 2017 Nov 3;19(21):5783-5785. doi: 10.1021/acs.orglett.7b02735.

14.
15.

Phosphazene-catalyzed desymmetrization of cyclohexadienones by dithiane addition.

Horwitz MA, Massolo E, Johnson JS.

Beilstein J Org Chem. 2017 Apr 24;13:762-767. doi: 10.3762/bjoc.13.75. eCollection 2017.

16.

Local Desymmetrization through Diastereotopic Group Selection: An Enabling Strategy for Natural Product Synthesis.

Horwitz MA, Johnson JS.

European J Org Chem. 2017 Mar 17;2017(11):1381-1390. doi: 10.1002/ejoc.201601481. Epub 2017 Feb 7.

17.

Correction to "Diastereoselective Organocatalytic Addition of α-Angelica Lactone to β-Halo-α-ketoesters".

Griswold JA, Horwitz MA, Leiva LV, Johnson JS.

J Org Chem. 2017 Jun 2;82(11):5995. doi: 10.1021/acs.joc.7b01160. Epub 2017 May 19. No abstract available.

PMID:
28524667
18.

Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron.

Stefanova D, Raychev A, Arezes J, Ruchala P, Gabayan V, Skurnik M, Dillon BJ, Horwitz MA, Ganz T, Bulut Y, Nemeth E.

Blood. 2017 Jul 20;130(3):245-257. doi: 10.1182/blood-2017-03-772715. Epub 2017 May 2.

19.

A Pathogen-Specific Cargo Delivery Platform Based on Mesoporous Silica Nanoparticles.

Ruehle B, Clemens DL, Lee BY, Horwitz MA, Zink JI.

J Am Chem Soc. 2017 May 17;139(19):6663-6668. doi: 10.1021/jacs.7b01278. Epub 2017 May 5.

PMID:
28437093
20.

Correction to "Diastereoselective Organocatalytic Addition of α-Angelica Lactone to β-Halo-α-ketoesters".

Griswold JA, Horwitz MA, Leiva LV, Johnson JS.

J Org Chem. 2017 Apr 7;82(7):4006. doi: 10.1021/acs.joc.7b00533. Epub 2017 Mar 13. No abstract available.

PMID:
28286943
21.

Diastereoselective Organocatalytic Addition of α-Angelica Lactone to β-Halo-α-ketoesters.

Griswold JA, Horwitz MA, Leiva LV, Johnson JS.

J Org Chem. 2017 Feb 17;82(4):2276-2280. doi: 10.1021/acs.joc.6b03059. Epub 2017 Feb 6. Erratum in: J Org Chem. 2017 Apr 7;82(7):4006. J Org Chem. 2017 Jun 2;82(11):5995.

22.

Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time.

Lee BY, Clemens DL, Silva A, Dillon BJ, Masleša-Galić S, Nava S, Ding X, Ho CM, Horwitz MA.

Nat Commun. 2017 Jan 24;8:14183. doi: 10.1038/ncomms14183.

23.

Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.

Jia Q, Bowen R, Lee BY, Dillon BJ, Masleša-Galić S, Horwitz MA.

Vaccine. 2016 Sep 22;34(41):4969-4978. doi: 10.1016/j.vaccine.2016.08.041. Epub 2016 Aug 28.

24.

Redox-Triggered Release of Moxifloxacin from Mesoporous Silica Nanoparticles Functionalized with Disulfide Snap-Tops Enhances Efficacy Against Pneumonic Tularemia in Mice.

Lee BY, Li Z, Clemens DL, Dillon BJ, Hwang AA, Zink JI, Horwitz MA.

Small. 2016 Jul;12(27):3690-702. doi: 10.1002/smll.201600892. Epub 2016 Jun 1.

PMID:
27246117
25.

Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model.

Silva A, Lee BY, Clemens DL, Kee T, Ding X, Ho CM, Horwitz MA.

Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):E2172-9. doi: 10.1073/pnas.1600812113. Epub 2016 Mar 28.

26.

Type I and Type II Interferon Coordinately Regulate Suppressive Dendritic Cell Fate and Function during Viral Persistence.

Cunningham CR, Champhekar A, Tullius MV, Dillon BJ, Zhen A, de la Fuente JR, Herskovitz J, Elsaesser H, Snell LM, Wilson EB, de la Torre JC, Kitchen SG, Horwitz MA, Bensinger SJ, Smale ST, Brooks DG.

PLoS Pathog. 2016 Jan 25;12(1):e1005356. doi: 10.1371/journal.ppat.1005356. eCollection 2016 Jan.

27.

Asymmetric Organocatalytic Reductive Coupling Reactions between Benzylidene Pyruvates and Aldehydes.

Horwitz MA, Zavesky BP, Martinez-Alvarado JI, Johnson JS.

Org Lett. 2016 Jan 4;18(1):36-9. doi: 10.1021/acs.orglett.5b03127. Epub 2015 Dec 14.

28.

Enantioselective reductive multicomponent coupling reactions between isatins and aldehydes.

Horwitz MA, Tanaka N, Yokosaka T, Uraguchi D, Johnson JS, Ooi T.

Chem Sci. 2015 Nov 1;6(11):6086-6090. Epub 2015 Jul 30.

29.

Tuberculosis: pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice (Small 38/2015).

Hwang AA, Lee BY, Clemens DL, Dillon BJ, Zink JI, Horwitz MA.

Small. 2015 Oct;11(38):5065. doi: 10.1002/smll.201570235.

PMID:
26450161
30.

Mesoporous Silica Nanoparticles with pH-Sensitive Nanovalves for Delivery of Moxifloxacin Provide Improved Treatment of Lethal Pneumonic Tularemia.

Li Z, Clemens DL, Lee BY, Dillon BJ, Horwitz MA, Zink JI.

ACS Nano. 2015 Nov 24;9(11):10778-89. doi: 10.1021/acsnano.5b04306. Epub 2015 Oct 9.

PMID:
26435204
31.

pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice.

Hwang AA, Lee BY, Clemens DL, Dillon BJ, Zink JI, Horwitz MA.

Small. 2015 Oct;11(38):5066-78. doi: 10.1002/smll.201500937. Epub 2015 Jul 20.

32.

Massively parallel delivery of large cargo into mammalian cells with light pulses.

Wu YC, Wu TH, Clemens DL, Lee BY, Wen X, Horwitz MA, Teitell MA, Chiou PY.

Nat Methods. 2015 May;12(5):439-44. doi: 10.1038/nmeth.3357. Epub 2015 Apr 6.

33.

Atomic structure of T6SS reveals interlaced array essential to function.

Clemens DL, Ge P, Lee BY, Horwitz MA, Zhou ZH.

Cell. 2015 Feb 26;160(5):940-951. doi: 10.1016/j.cell.2015.02.005.

34.
35.

Characterization of a Mycobacterium tuberculosis nanocompartment and its potential cargo proteins.

Contreras H, Joens MS, McMath LM, Le VP, Tullius MV, Kimmey JM, Bionghi N, Horwitz MA, Fitzpatrick JA, Goulding CW.

J Biol Chem. 2014 Jun 27;289(26):18279-89. doi: 10.1074/jbc.M114.570119. Epub 2014 May 22.

36.

The exochelins of pathogenic mycobacteria: unique, highly potent, lipid- and water-soluble hexadentate iron chelators with multiple potential therapeutic uses.

Horwitz LD, Horwitz MA.

Antioxid Redox Signal. 2014 Dec 1;21(16):2246-61. doi: 10.1089/ars.2013.5789. Epub 2014 Jun 20. Review.

37.

Bacillus Calmette-Guerin vaccine-mediated neuroprotection is associated with regulatory T-cell induction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Laćan G, Dang H, Middleton B, Horwitz MA, Tian J, Melega WP, Kaufman DL.

J Neurosci Res. 2013 Oct;91(10):1292-302. doi: 10.1002/jnr.23253. Epub 2013 Aug 1.

39.

Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles.

Clemens DL, Lee BY, Xue M, Thomas CR, Meng H, Ferris D, Nel AE, Zink JI, Horwitz MA.

Antimicrob Agents Chemother. 2012 May;56(5):2535-45. doi: 10.1128/AAC.06049-11. Epub 2012 Feb 21.

41.

Intravital imaging reveals limited antigen presentation and T cell effector function in mycobacterial granulomas.

Egen JG, Rothfuchs AG, Feng CG, Horwitz MA, Sher A, Germain RN.

Immunity. 2011 May 27;34(5):807-19. doi: 10.1016/j.immuni.2011.03.022. Epub 2011 May 19.

42.

Discovery and characterization of a unique mycobacterial heme acquisition system.

Tullius MV, Harmston CA, Owens CP, Chim N, Morse RP, McMath LM, Iniguez A, Kimmey JM, Sawaya MR, Whitelegge JP, Horwitz MA, Goulding CW.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5051-6. doi: 10.1073/pnas.1009516108. Epub 2011 Mar 7.

44.

The Mycobacterium bovis bacille Calmette-Guerin phagosome proteome.

Lee BY, Jethwaney D, Schilling B, Clemens DL, Gibson BW, Horwitz MA.

Mol Cell Proteomics. 2010 Jan;9(1):32-53. doi: 10.1074/mcp.M900396-MCP200. Epub 2009 Oct 7.

45.

Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.

Sun R, Skeiky YA, Izzo A, Dheenadhayalan V, Imam Z, Penn E, Stagliano K, Haddock S, Mueller S, Fulkerson J, Scanga C, Grover A, Derrick SC, Morris S, Hone DM, Horwitz MA, Kaufmann SH, Sadoff JC.

Vaccine. 2009 Jul 16;27(33):4412-23. doi: 10.1016/j.vaccine.2009.05.048. Epub 2009 Jun 2.

PMID:
19500523
46.

Francisella tularensis phagosomal escape does not require acidification of the phagosome.

Clemens DL, Lee BY, Horwitz MA.

Infect Immun. 2009 May;77(5):1757-73. doi: 10.1128/IAI.01485-08. Epub 2009 Feb 23.

47.

Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis.

Jia Q, Lee BY, Clemens DL, Bowen RA, Horwitz MA.

Vaccine. 2009 Feb 18;27(8):1216-29. doi: 10.1016/j.vaccine.2008.12.014. Epub 2009 Jan 4.

48.

Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis.

Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S.

Vaccine. 2009 Jan 14;27(3):441-5. doi: 10.1016/j.vaccine.2008.10.058. Epub 2008 Nov 11.

49.

A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers.

Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, Soler JH, Weichold F, Geiter L, Sadoff JC, Horwitz MA.

J Infect Dis. 2008 Nov 15;198(10):1491-501. doi: 10.1086/592450.

50.

A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.

Tullius MV, Harth G, Maslesa-Galic S, Dillon BJ, Horwitz MA.

Infect Immun. 2008 Nov;76(11):5200-14. doi: 10.1128/IAI.00434-08. Epub 2008 Aug 25.

Supplemental Content

Loading ...
Support Center